Video Series

Learn how tumor and liquid biopsy biomarker tests are ordered, why results take weeks, and how insurance rules can delay cancer treatment.

This episode, titled 'Risk Stratification and Weight Loss as Therapy: A Hepatologist's Framework for Managing MASH Progression,' features Nadege Gunn, MD discussing the following critical questions: 1. How do you risk-stratify your patients, and what clinical or metabolic factors most reliably predict progression? 2. What does the literature tell us about the relationship between meaningful weight loss and fibrosis regression, and how does that inform your thinking about weight-loss therapy as a hepatic intervention?

In 'Screening MASH Upstream: Building a Practical, Scalable Algorithm for the Real World,’ Nadege Gunn, MD delves into the following critical question: 1. There is growing interest in screening for MASH further upstream. What would a practical, scalable screening algorithm look like in your view, and what are the limitations of that approach?

Payer delays and unpredictable coverage stall mental health meds, worsening symptoms, work performance, and ER risk while forcing clinicians into inefficient trial-and-error care.

Clinicians weigh generics versus new psychiatric meds, emphasizing evidence for treatment-resistant cases, staying current, and balancing costs, side effects, and whole-person care.

Learn how tumor and liquid biopsy testing fits care—plus insurance hurdles, turnaround delays, and the push for faster NGS results.

Angela Lamb examined the real-world challenges of capturing patient-reported outcomes in clinical practice, noting that while standardized pre-visit assessments and long-term tracking of quality of life and itch scores are theoretically ideal, implementation barriers such as varying electronic medical record (EMR) systems and competing clinical demands make consistent adoption difficult outside of clinical trial settings.

Explore evolving biomarker testing for rare neuroendocrine carcinomas—NGS, MSI/TMB, and emerging DLL3 targets guiding new trials.

In this episode, 'Screening, Risk Stratification, and the Multidisciplinary Care Model for MASH,' the hepatologist Nadege Gunn, MD explores the following questions: 1. How would you characterize the urgency of MASH as a public health problem for a primary care physician who may see the early signs? 2. In an ideal world, what does the multidisciplinary care model for a MASH patient with significant obesity look like? How far is current clinical practice from that ideal, and where do the current gaps exist?

Welcome back to another AJMC Insights series. In this episode titled, 'MASH in Focus: How Patient Awareness, Clinical Empowerment, and Research Have Transformed the Field,' Nadege Gunn, MD led the conversation about the following questions: 1. As a hepatologist, how has the MASH patient population changed over the last decade? 2. Do you feel the broader medical community has kept pace with that shift? 3. How much of your current liver disease caseload would you attribute to metabolic and obesity-driven disease versus other etiologies?

Clinicians unpack why meds fail—patient fit, side effects, and adherence—and share practical ways to boost understanding and remission.

In this AJMC Insights episode, Angela Lamb discusses how clinicians diagnose and assess atopic dermatitis using clinical scoring tools and patient-centered goal setting, emphasizing the importance of evaluating both disease severity and patient-reported symptoms to guide individualized treatment decisions.

Experts explain evolving biomarker testing for rare neuroendocrine carcinomas, from NCCN gaps to DLL3 and NGS, guiding trials and treatment.

Learn how aggressive neuroendocrine carcinoma disrupts daily life—and why rapid treatment, strong caregiver support, and navigation resources matter.

Clinicians battle insurance formularies, using evidence, step-therapy strategy, and two‑week outcome tracking to secure affordable psychiatric meds.

Clinicians navigate insurance formularies, prior authorizations, and step therapy—using 14‑day check-ins and PHQ‑9 data to win better meds.

Experts warn extrapulmonary neuroendocrine carcinomas are often missed; faster pathology, rapid referrals, and early treatment improve survival.

Rare neuroendocrine carcinomas outside the lung often go missed; expert pathology and rapid referrals enable earlier treatment and better outcomes.

How health systems break silos with multidisciplinary, patient-centered teams to improve CRM outcomes through coordinated, holistic care.

Clinicians weigh antipsychotic choices with patients, tracking labs and side effects, while navigating insurance and brand-vs-generic variability.

Experts reveal how stigma, misdiagnosis, and cost barriers delay depression, bipolar, and schizophrenia care—and what breaks the crisis cycle.

How combined therapies and proactive, team-based CRM care cut costs, streamline meds, and improve heart, kidney, and metabolic outcomes.

The panelists examined how the scarcity of mental health specialists creates a cascading effect on care capacity, where patients who do not respond to initial primary care treatment face an increasingly narrow pool of expert clinicians equipped to manage complex, refractory cases.

Learn how rare neuroendocrine cancers are diagnosed, why pathology and Ki-67 guide care, and how teams coordinate chemo, trials, support.

New factor XIa inhibitors cut recurrent non-cardioembolic stroke without extra bleeding—plus what milvexian and abilacimab trials reveal.

Experts unpack neuroendocrine carcinoma vs tumors, key pathology markers, and high-risk features shaping prognosis and treatment decisions.

Factor XIa blockers aim to prevent stroke-driving clots with less bleeding; explore leading phase 3 drugs and oral vs IV tradeoffs.